Negative allosteric modulators that target human α4β2 neuronal nicotinic receptors

Journal of Pharmacology and Experimental Therapeutics

Volumn 334, Issue 3, 2010, Pages 761-774

  Henderson, Brandon J ^a   Pavlovicz, Ryan E ^a   Allen, Jerad D ^a   González Cestari, Tatiana F ^a   Orac, Crina M ^c   Bonnell, Andrew B ^b   Zhu, Michael X ^b   Boyd, R Thomas ^b   Li, Chenglong ^a   Bergmeier, Stephen C ^c   McKay, Dennis B ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c OHIO UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APB 8; COB 1; COB 2; COB 3; COB 4; DDR 1; DDR 13; DDR 15; DDR 18; DDR 19; DDR 2; DDR 5; EPIBATIDINE; IB 2; IB 4; KAB 18; KAB 19; KAB 20; KAB 21; KAB 22; KAB 23; KAB 24; KAB 30; MECAMYLAMINE; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR ALPHA4BETA2; NICOTINIC RECEPTOR BLOCKING AGENT; PPB 13; TUBOCURARINE CHLORIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; BIPHENYL DERIVATIVE; FUSED HETEROCYCLIC RINGS; KAB-18; NICOTINIC RECEPTOR; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE;

ARTICLE; DRUG ACTIVITY; DRUG BINDING; DRUG SELECTIVITY; GENE MUTATION; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; MUTAGENESIS; NERVE CELL; NEUROMODULATION; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; ALGORITHM; CELL LINE; CHEMICAL STRUCTURE; DRUG EFFECTS; GENETICS; HYDROGEN BOND; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ALGORITHMS; BICYCLO COMPOUNDS, HETEROCYCLIC; BIPHENYL COMPOUNDS; CELL LINE; HUMANS; HYDROGEN BONDING; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; NEURONS; NICOTINIC AGONISTS; PIPERIDINES; PYRIDINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTORS, NICOTINIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77956253387     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.168211     Document Type: Article

References (38)

1. Anand R, Conroy WG, Schoepfer R, Whiting P, and Lindstrom J (1991) Neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes have a pentameric quaternary structure. J Biol Chem 266:11192-11198.
2. Arias HR (1998) Binding sites for exogenous and endogenous non-competitive inhibitors of the nicotinic acetylcholine receptor. Biochim Biophys Acta 1376:173-220.
3. Bergmeier SC, Ismail KA, Arason KM, McKay S, Bryant DL, and McKay DB (2004) Structure activity studies of ring E analogues of methyllycaconitine. Part 2: synthesis of antagonists to the α3β4 nicotinic acetylcholine receptors through modifications to the ester. Bioorg Med Chem Lett 14:3739-3742.
4. Bergmeier SC, Lapinsky DJ, Free RB, and McKay DB (1999) Ring E analogs of methyllycaconitine (MLA) as novel nicotinic antagonists. Bioorg Med Chem Lett 9:2263-2266.
5. Bryant DL, Free RB, Thomasy SM, Lapinsky DJ, Ismail KA, McKay SB, Bergmeier SC, and McKay DB (2002) Structure-activity studies with ring E analogues of methyllycaconitine on bovine adrenal α3β4* nicotinic receptors. Neurosci Res 42:57-63.
6. Case DA, Cheatham TE 3rd, Darden T, Gohlke H, Luo R, Merz KM Jr, Onufriev A, Simmerling C, Wang B, and Woods RJ (2005) The Amber biomolecular simulation programs. J Comput Chem 26:1668-1688.
7. Changeux JP, Pinset C, and Ribera AB (1986) Effects of chlorpromazine and phencyclidine on mouse c2 acetylcholine receptor kinetics. J Physiol 378:497-513.
8. Cooper E, Couturier S, and Ballivet M (1991) Pentameric structure and subunit stoichiometry of a neuronal nicotinic acetylcholine receptor. Nature 350:235-238.
9. Cramer RD (2003) Topomer CoMFA: a design methodology for rapid lead optimization. J Med Chem 46:374-388.
10. 125I] iodophenyl) diazirine and tetracaine, phencyclidine, or histrionicotoxin in the torpedo species nicotinic acetylcholine receptor ion channel. Mol Pharmacol 59:1514-1522.
11. González-Cestari TF, Henderson BJ, Pavlovicz RE, McKay SB, El-Hajj RA, Pulipaka AB, Orac CM, Reed DD, Boyd RT, Zhu MX, et al. (2009) Effect of novel negative allosteric modulators of neuronal nicotinic receptors on cells expressing native and recombinant nicotinic receptors: implications for drug discovery. J Pharmacol Exp Ther 328:504-515.
12. Gotti C, Riganti L, Vailati S, and Clementi F (2006) Brain neuronal nicotinic receptors as new targets for drug discovery. Curr Pharm Des 12:407-428.
13. Grinevich VP, Papke RL, Lippiello PM, and Bencherif M (2009) Atypical antipsychotics as noncompetitive inhibitors of α4β2 and α7 neuronal nicotinic receptors. Neuropharmacology 57:183-191.
14. Hall BJ, Pearson LS, and Buccafusco JJ (2010) Effect of administration of the nicotinic acetylcholine receptor antagonist BTMPS, during nicotine self-administration, on lever responding induced by context long after withdrawal. Neuropharmacology 58:429-435.
15. Hansen SB and Taylor P (2007) Galanthamine and non-competitive inhibitor binding to ACh-binding protein: evidence for a binding site on non-α-subunit interfaces of heteromeric neuronal nicotinic receptors. J Mol Biol 369:895-901.
16. Huang J, Orac CM, McKay S, McKay DB, and Bergmeier SC (2008) The synthesis of 5-substituted ring E analogs of methyllycaconitine via the Suzuki-Miyaura cross-coupling reaction. Bioorg Med Chem 16:3816-3824.
17. Iorga B, Herlem D, Barré E, and Guillou C (2006) Acetylcholine nicotinic receptors: finding the putative binding site of allosteric modulators using the "blind docking" approach. J Mol Model 12:366-372.
18. Jensen AA, Frølund B, Liljefors T, and Krogsgaard-Larsen P (2005) Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. J Med Chem 48:4705-4745.
19. Lloyd GK and Williams M (2000) Neuronal nicotinic acetylcholine receptors as novel drug targets. J Pharmacol Exp Ther 292:461-467.
20. Lukas RJ, Changeux JP, Le Novère N, Albuquerque EX, Balfour DJ, Berg DK, Bertrand D, Chiappinelli VA, Clarke PB, Collins AC, et al. (1999) International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev 51:397-401.
21. McKay DB and Burkman AM (1993) Nicotinic and non-nicotinic receptor-mediated actions of vinblastine. Proc Soc Exp Biol Med 203:372-376.
22. McKay DB and Trent-Sanchez P (1990) Effect of noncompetitive nicotinic receptor blockers on catecholamine release from cultured adrenal chromaffin cells. Pharmacology 40:224-230.
23. McKay DB, Chang C, González-Cestari TF, McKay SB, El-Hajj RA, Bryant DL, Zhu MX, Swaan PW, Arason KM, Pulipaka AB, et al. (2007) Analogs of methyllycaconitine as novel noncompetitive inhibitors of nicotinic receptors: pharmacological characterization, computational modeling, and pharmacophore development. Mol Pharmacol 71:1288-1297.
24. Moaddel R, Jozwiak K, and Wainer IW (2007) Allosteric modifiers of neuronal nicotinic acetylcholine receptors: new methods, new opportunities. Med Res Rev 27:723-753.
25. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, and Olson AJ (1998) Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function. J Comput Chem 19:1639-1662.
26. Nelson ME, Kuryatov A, Choi CH, Zhou Y, and Lindstrom J (2003) Alternate stoichiometries of α4β2 nicotinic acetylcholine receptors. Mol Pharmacol 63:332-341.
27. Nelson ME, Wang F, Kuryatov A, Choi CH, Gerzanich V, and Lindstrom J (2001) Functional properties of human nicotinic AChRs expressed by IMR-32 neuroblastoma cells resemble those of α3β4 AChRs expressed in permanently transfected HEK cells. J Gen Physiol 118:563-582.
28. Olale F, Gerzanich V, Kuryatov A, Wang F, and Lindstrom J (1997) Chronic nicotine exposure differentially affects the function of human α3, α4, and α7 neuronal nicotinic receptor subtypes. J Pharmacol Exp Ther 283:675-683.
29. Papke RL, Sanberg PR, and Shytle RD (2001) Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes. J Pharmacol Exp Ther 297:646-656.
30. Pepin MC, Yue SY, Roberts E, Wahlestedt C, and Walker P (1997) Novel "restoration of function" mutagenesis strategy to identify amino acids of the -opioid receptor involved in ligand binding. J Biol Chem 272:9260-9267.
31. Pratt MB, Pedersen SE, and Cohen JB (2000) Identification of the sites of incorporation of [3H] ethidium diazide within the torpedo nicotinic acetylcholine receptor ion channel. Biochemistry 39:11452-11462.
32. Rose JE, Behm FM, Westman EC, Levin ED, Stein RM, and Ripka GV (1994) Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin Pharmacol Ther 56:86-99.
33. Rose JE, Behm FM, and Westman EC (1998) Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy. Exp Clin Psychopharmacol 6:331-343.
34. Selent U, Rüter T, Köhler E, Liedtke M, Thielking V, Alves J, Oelgeschläger T, Wolfes H, Peters F, and Pingoud A (1992) A site-directed mutagenesis study to identify amino acid residues involved in the catalytic function of the restriction endonuclease EcoRV. Biochemistry 31:4808-4815.
35. Stauderman KA, Mahaffy LS, Akong M, Veliçelebi G, Chavez-Noriega LE, Crona JH, Johnson EC, Elliott KJ, Gillespie A, Reid RT, et al. (1998) Characterization of human recombinant neuronal nicotinic acetylcholine receptors subunit combinations of α2β4, α3β4 and α4β4 stably expressed in HEK293 cells. J Pharmacol Exp Ther 284:777-789.
36. Wang F, Gerzanich V, Wells GB, Anand R, Peng X, Keyser K, and Lindstrom J (1996) Assembly of human neuronal nicotinic receptor α 5 subunits with α3, β2, and β4 subunits. J Biol Chem 271:17656-17665. (Pubitemid 26250735)
37. Yoshimura RF, Hogenkamp DJ, Li WY, Tran MB, Belluzzi JD, Whittemore ER, Leslie FM, and Gee KW (2007) Negative allosteric modulation of nicotinic acetylcholine receptors blocks nicotine self-administration in rats. J Pharmacol Exp Ther 323:907-915.
38. Young GT, Broad LM, Zwart R, Astles PC, Bodkin M, Sher E, and Millar NS (2007) Species selectivity of a nicotinic acetylcholine receptor agonist is conferred by two adjacent extracellular β4 amino acids that are implicated in the coupling of binding to channel gating. Mol Pharmacol 71:389-397.